Immuno-Oncology Overview 2017: CAR-T Cell Therapy Early Clinical Results are Extremely Promising - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Immuno-Oncology Overview" report has been added to ResearchAndMarkets.com's offering.

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well as one of the most active areas in terms of licensing deals and acquisitions.

Highlights

• The PD-1/PD-L1 inhibitor and TCR/CAR-T therapy drug classes lead the development of all immuno-oncology drugs. However, several novel mechanisms of action are also in early-phase development.
• Developers of approved PD-1/PD-L1 inhibitors - Bristol-Myers Squibb, Merck & Co, Roche, AstraZeneca, and Pfizer - currently dominate the immuno-oncology field in terms of the number of ongoing, conducted, and planned trials.
• Furthermore, PD-1/PD-L1 inhibitors remain a focal point of immuno-oncology combinations, with various types of combination approaches being studied.

Key Topics Covered:

1. Executive Summary
2. Immuno-Oncology Overview
3. Current Status Of Immuno-Oncology Development
4. Pd-1/Pd-L1 Inhibitors
5. Ctla-4 Inhibitors
6. Tcr And Car-T Therapies
7. Ido Inhibitors
8. Emerging Drug Classes
9. Bristol-Myers Squibb
10. Merck & Co
11. Roche
12. Astrazeneca
13. Pfizer
14. Immuno-Oncology Combinations
15. Kol Survey
16. Kol Interviews

For more information about this report visit https://www.researchandmarkets.com/research/mx83p9/immunooncology?w=4